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Background: Proton pump inhibitors (PPI) are a widely-used class of drugs for the treatment of gastro-esophageal
reflux disease and other acid-related disorders of the gastrointestinal tract. As a class, PPIs have demonstrated a
favorable safety profile. However, case reports have suggested that this class of drugs may be linked to acute
kidney injury, which may in turn lead to chronic injury or failure. The objective of this study was to determine if an
association between PPIs and kidney failure exists and to estimate an effect size for the relationship between PPI
use and renal disease.
Methods: A nested case–control study was conducted in a privately insured population in a single Midwestern
state including a total of 184,480 patients aged 18 years or older who were continuously enrolled with the insurer
for at least 24 months between September 2002 and November 2005.
Of the patients eligible for the study, 854 cases were identified as having at least two claims for an acute renal
disease diagnosis. Cases were randomly matched with up to four controls (n = 3,289) based on age, gender, county
of residence, and date of entry into the cohort. Patient demographic data, PPI use, illnesses, and medications
associated with renal disease and a proxy for health status using pre-existing patient comorbidities were collected
from inpatient, professional, and prescription claims data. Conditional logistic regression models were used to
evaluate the association between renal disease and PPI use.
Results: Renal disease was positively associated with PPI use (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.27,
2.32, p < 0.001) even after controlling for potential confounding conditions. After removing patients with potential
confounding disease states from the study population, the number of cases (195 of the 854) and controls (607) was
lower, but the relationship between renal disease and PPI use remained consistent (OR 2.25, CI 1.09-4.62, p < 0.001).
Conclusions: Patients with a renal disease diagnosis were twice as likely to have used a previous prescription for a
PPI. Therefore, it is necessary for physicians to increase recognition of patient complaints or clinical manifestations
of this potentially harmful event in order to prevent further injury.
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Proton pump inhibitors (PPI) are a widely-used class of
drugs for the treatment of gastro-esophageal reflux disease
and other acid-related disorders of the gastrointestinal
tract. In 2009, more than 119 million PPI prescriptions
were filled in the United States, accounting for nearly $14
billion dollars in prescription PPI sales, in addition to
billions more in over-the-counter (OTC) sales [1]. The
PPI class includes several different agents, such as esome-* Correspondence: dklepser@unmc.edu
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reproduction in any medium, provided the orprazole, omeprazole, lansoprazole, pantoprazole, deslanso-
prazole, rabeprazole, etc., all of which possess a common
mechanism of action for reducing parietal cell acid produc-
tion by blocking H+/K + adenosine triphosphatase [2,3].
As a class, PPIs have demonstrated a favorable safety
profile [4-6]. Overall, complications have been infrequent
and minor. The most common unwanted effects reported
have been headaches, abdominal pain, and diarrhea [2]. In
fact, the favorable adverse effect profile has led to move-
ment of some of these agents to non-prescription status.
However, as the use of PPIs has grown more widespread
so have safety concerns. A growing body of literatureLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





Hypertensive renal disease 403.XX
Acute glomerulonephritis 580.XX 580.89
Nephrotic syndrome 581.XX
Chronic glomerulonephritis 582.XX
Nephritis and nephropathy 583.XX 583.81, 583.89, 583.9
Acute renal failure 584.XX 584.8, 584.9
Chronic renal failure 585.XX
Renal failure, unspecified 586.XX 586.XX
Impaired renal function disease
NECb
588.89





a ICD-9 International Classification of Diseases, Ninth Revision.
b NEC not elsewhere classifiable.
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kidney injury, which can potentially lead to chronic injury
or kidney failure. In 1992, a sentinel case-report identified
the PPI omeprazole as a possible cause of acute interstitial
nephritis (AIN) in an elderly woman [7]. Since that time,
numerous biopsy-confirmed case reports and retrospec-
tive descriptive reports have been published suggesting a
connection between PPI use and AIN [8-10]. Detailed
summaries of these case reports have been published
[9,11,12]. However, research in this area has been limited
and consisted of small sample sizes without comparator
groups. As a result, no estimate of the effect size is
currently available. In turn, determining if an association
between PPI use and AIN exists requires studies using
larger sample sizes and control groups.
Drug-induced AIN is a form of acute kidney injury
thought to result from an idiosyncratic, cell-mediated
immunologic reaction [13,14]. Drugs are the most com-
monly cited cause of AIN, but infectious and immune
etiologies are also possible [15]. Recognition of AIN is
elusive as the clinical manifestations are subtle. Classically,
AIN has been described to present the following triad of
events: fever, rash, and arthralgias [16-18]. Unfortunately,
in case-reports of PPI-induced AIN, the triad of symptoms
was present in a minority of subjects. Most complaints
were nonspecific, including fever, fatigue/lethargy, weight
loss, and nausea/vomiting [9,11,12]. Laboratory abnorma-
lities were more consistently present in PPI-induced AIN
cases, with elevated serum creatinine, pyuria, proteinuria,
and hematuria observed in over 60% of the cases
[9,11,19]. Because of varied clinical presentation and lack
of accurate non-invasive tests, AIN can only be definitively
diagnosed through a renal biopsy [13,18].
In practice, PPI-induced AIN is likely under- or mis-
diagnosed due to low suspicion (infrequent occurrence,
limited information dissemination) and inconsistent
clinical presentation [12]. Rather, AIN is more likely to
be classified as some other form of acute or chronic
renal injury. Recognizing this mis-classification, studies
using claims data to investigate a link between PPI use
and AIN require broadening ICD-9 codes beyond the
single heading “AIN”. The objective of this study was to
determine if an association exists between renal injury
and PPI use and in turn estimate an effect size for this
association using claims data.
Methods
This retrospective nested case–control study used claims
data from a private insurer in a single Midwestern state
to examine the relationship between renal disease and
prescription PPI use. The nested case–control design
has been employed in pharmacoepidemiologic studies,
and its strengths and limitations have been previously
described [20-22]. The insurer’s databases included39 months (September 2002 through November 2005)
of inpatient, outpatient, and prescription claims for a
cohort of 184,480 patients. The database has been used in
a number of studies and is a generally complete claims
record for covered patients [23-25]. Patient identifiers
were encrypted but could be linked across medical and
prescription claims databases and years as long as the
patient had coverage during these years. The study was
approved by the University of Nebraska Medical Center
Institutional Review Board.
Study cohort
Using demographic data and dates of coverage provided
by the insurer, patients under the age of 18 and with less
than two years of continuous coverage during the study
period were excluded from the study. Patients diagnosed
with renal disease (Table 1) within their first 12 months
of entry into the cohort (i.e., the beginning of the study
period or start of their continuous coverage) were also
excluded from the study. Patients included in the study
were 18 years or older, diagnosed with renal disease for
at least 12 months, and continuously enrolled with the
insurer for at least 24 months between September 2002
and November 2005. These inclusion and exclusion
criteria assured that all patients had at least twelve months
of claims data prior to the onset of renal disease.
Case and control definition
Given that the true nature of PPI-induce renal injury (i.e.,
AIN) is frequently misdiagnosed, multiple ICD-9 codes
for acute or chronic renal disease were used to capture
un-recognized cases. A practicing nephrologist was asked
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universe of ICD-9 codes that could be used to bill for
AIN. Cases were defined as patients with at least two renal
disease claims following 12 months of coverage within the
study period. At least two claims were required to ensure
that the first claim was not merely a diagnostic test used
to rule out a renal disease.
Each case was then matched, using incident density
sampling based on age, gender, county, and initial date
of coverage with up to four randomly selected controls.
Cases and controls were matched with the initial date of
insurance coverage to account for changes in treatment
patterns over the course of the study and to allow for
the assignment of a common index date for each case
and its controls. The index date was the service date of
each case’s first renal disease claim and was assigned to
both the cases and matched controls to determine the
timing of PPI use and the presence of potential con-
founders at the time of diagnosis.
Covariates
PPI exposure status was obtained through prescription
claims. Exposure was defined as having a PPI claim in
the 90 days prior to the index date. Recognizing that our
definition of renal injury includes cases not related to
PPI use, we used a multi-variable regression to control
for the effect of these confounding causes of renal injury.
Potential confounders in this study were illnesses and
the use of prescription medications that have been previ-
ously shown to be associated with renal disease [26].
These potential cofounders include diabetes, hyperten-
sion, high cholesterol, and antibiotic, diuretic, or use of
non-steroidal anti-inflammatory drugs (NSAID). Use of
OTC medications is not captured in a claims data base.
Confounding by health status is an important conside-
ration because patients with a lower health status are
more likely to 1) have a renal disease diagnosis and 2)
use PPIs [27]. As a proxy for patient health status, we
included comorbidities from the Deyo modification of
the Charlson comorbidity index as potential cofounding
variables that were not previously included (i.e., myo-
cardial infarction, congestive heart failure, peripheral
vascular disease, cerebrovascular disease, hemiplegia or
paraplegia, dementia, chronic pulmonary disease, rheu-
matologic disease, mild liver disease, moderate or severe
liver disease, AIDS, malignancy, and metastatic solid
tumor) [28]. All variables were extracted from inpatient,
outpatient, and prescription claims data using appro-
priate ICD-9 and NDC codes. Claims were not gene-
rated for OTC PPI or NSAID purchases and therefore
this utilization was not captured. The presence of a
confounding variable was concluded if a claim was iden-
tified in the period (minimum 12 months) prior to the
index date.Data analysis
We elected to explore the association between PPI-use
and renal injury using two models. The first model
attempts to control for potential confounding variables
associated with renal disease, as listed above in the Covari-
ates section. Conditional logistic regression models were
used to calculate odds ratios (ORs) and 95% Confidence
Intervals (CIs). All potential predictors were first evaluated
in univariable conditional logistic regression models.
Those covariates reaching a univariable significance level
of p ≤ 0.1 were included in the final multivariable model.
The p values corresponding to regression models are
based on the Wald test.
Recognizing that some residual confounding variables
could remain in the first model, a second conditional
logistic regression model excluded cases and controls
with pre-existing diagnoses for the comorbidities included
in the primary model. As an additional sensitivity analysis,
a conditional logistic regression model was used that
included propensity scores. The propensity score and
predicted probabilities of using a PPI were computed
using all remaining independent variables. Finally, the
authors conducted an analyses using Histamine-2 Receptor
Antagonists (H2 Blockers), which have not been linked to
acute kidney injury. All analyses were generated using SAS/
STAT software, Version 9.2 of the SAS System for Win-
dows (Copyright SAS Institute Inc.). SAS and all other SAS
Institute Inc. product or service names are registered trade-
marks or trademarks of SAS Institute Inc., Cary, NC, USA.
Results
In the primary model, 854 cases of renal disease were
matched to 3,289 controls. Of the 854 cases, 727 (85.1%)
were matched to four controls, while the remaining 127
(14.9%) were matched to three controls. As Table 2
shows, most of the identified renal disease diagnoses
were for acute renal insufficiency and acute renal failure.
Cases were more likely to use a PPI and were conside-
rably sicker, higher prevalence chronic diseases, (Table 3)
than controls. Renal disease was positively associated
with PPI use (OR = 2.04; CI 1.53, 2.71) even after con-
trolling for potential confounding conditions (Table 4).
Given the incidence in this population (0.0046), the
number needed to harm equals 303 patients.
After removing patients with potential confounding
disease states from the study population, the number of
cases (195) and controls (607) decreased (Table 5).
Despite the smaller population, the relationship between
renal disease and PPI use remained consistent (OR = 2.25;
CI 1.09, 4.62).
The inclusion of a propensity score in the model did
not change the relationship between PPI use and renal
disease (OR 2.05, CI 1.52, 2.72). Analyses of H2 Blockers
showed that there was not a statistically significant
Table 2 Cases by diagnosis frequency
ICD-9a Description Primary model (n = 854) Secondary model (n = 195)
580.89 Acute interstitial nephritis 3 (0.35%) 0 (0.00%)
583.81 Nephritis NOS in other disease 17 (1.99%) 1 (0.50%)
583.89 Nephritis NECb 4 (0.47%) 1 (0.50%)
583.9 Nephritis NOSc 31 (3.63%) 8 (4.00%)
584.8 Acute renal failure NEC 1 (0.12%) 0 (0.00%)
584.9 Acute renal failure NOS 147 (17.21%) 30 (15.00%)
586 Renal failure NOS 47 (5.50%) 6 (3.00%)
593.9 Acute renal insufficiency 605 (70.84%) 149 (77.00%)
a ICD-9 International Classification of Diseases, Ninth Revision.
b NEC not elsewhere classifiable.
c NOS not otherwise specified.
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(OR 1.37, CI 0.46, 4.13).
To account for the potential that a 90 day exposure
status may include patients not currently using PPIs,
sensitivity analyses using a 15 and 30 exposure window
were also conducted. The results, not presented, were
consistent with and confirmed the base case analyses.Table 3 Characteristics of cases and controls
Variable Cases (n = 854) Controls
Agec 51.09 (9.53) 51.10
Genderc
Female 397 (46.5%) 1525
Male 457 (53.5%) 1764
PPId use 126 (14.8%) 191
NSAIDe use 293 (34.3%) 703
Antibiotic use 202 (26.7%) 223
Diuretic use 215 (25.2%) 293
Diabetes 175 (20.5%) 216
Hypertension 302 (35.4%) 626
High cholesterol 238 (27.8%) 659
Myocardial infarction 13 (1.5%) 18
Congestive heart failure 38 (4.5%) 8 (
Cerebrovascular disease 15 (1.8%) 12
Peripheral vascular disease 26 (3.0%) 17
Paralysis 6 (0.7%) 4 (
Chronic lung disease 45 (5.3%) 47
Liver disease 16 (1.9%) 9 (
Malignancy 49 (5.7%) 28
Metastatic cancer 27 (3.2%) 9 (
Rheumatoid arthritis 13 (1.5%) 10
Osteoarthritis 72 (8.4%) 184
a OR odds ratio.
b CI confidence interval.
c Cases and controls were matched on age and gender so those variables were not
d PPI proton pump inhibitor.
e NSAID nonsteroidal anti-inflammatory drugs.Similarly, inclusion of just incident users (first PPI
prescription within 90 days) confirmed the results of the
base case analyses.
Discussion
Previous publications have suggested an association




(5.8%) 2.91 (2.28-3.72) < 0.001
(21.4%) 1.97 (1.67-2.33) < 0.001
(6.8%) 4.41 (3.55-5.47) <0.001
(8.9%) 3.50 (2.86-4.27) <0.001
(6.6%) 3.94 (3.14-4.94) < 0.001
(19.0%) 2.48 (2.08-2.95) < 0.001
(20.0%) 1.58 (1.32-1.89) < 0.001
(0.5%) 2.86 (1.40-5.84) 0.004
0.2%) 18.20 (8.48-39.06) < 0.001
(0.4%) 5.28 (2.42-11.52) < 0.001
(0.5%) 6.19 (3.31-11.56) < 0.001
0.1%) 5.99 (1.69-21.24) 0.006
(1.4%) 3.94 (2.58-6.00) < 0.001
0.3%) 6.94 (3.06-15.72) < 0.001
(0.9%) 6.90 (4.33-10.97) < 0.001
0.3%) 12.00 (5.64-25.51) < 0.001
(0.3%) 4.95 (2.16-11.35) < 0.001
(5.6%) 1.57 (1.18-2.10) 0.002
compared statistically.
Table 4 Odds ratios of renal disease from a multiple
regression model
Variable Adjusted ORa 95% CIb P value
PPIc use 1.72 (1.27-2.32) < 0.001
NSAIDd use 1.64 (1.35-2.00) < 0.001
Antibiotic use 3.66 (2.86-4.68) <0.001
Diuretic use 2.28 (1.78-2.92) <0.001
Diabetes 2.74 (2.09-3.60) < 0.001
Hypertension 1.51 (1.21-2.89) < 0.001
High cholesterol 1.10 (0.89-1.37) 0.388
Myocardial infarction 0.63 (0.21-1.89) 0.409
Congestive heart failure 9.51 (3.90-23.20) < 0.001
Cerebrovascular disease 3.65 (1.28-10.43) 0.016
Peripheral vascular 4.20 (1.83-9.66) < 0.001
Paralysis 1.37 (0.25-7.34) 0.717
Chronic lung disease 1.81 (1.03-3.17) 0.040
Liver disease 7.38 (2.88-18.91) < 0.001
Malignancy 3.72 (2.07-6.70) < 0.001
Metastatic cancer 8.86 (3.35-23.44) < 0.001
Rheumatoid arthritis 2.62 (0.97-7.13) 0.058
Osteoarthritis 0.83 (0.60-1.21) 0.373
a OR odds ratio.
b CI confidence interval.
c PPI proton pump inhibitor.
d NSAID nonsteroidal anti-inflammatory drugs.
Klepser et al. BMC Nephrology 2013, 14:150 Page 5 of 7
http://www.biomedcentral.com/1471-2369/14/150[7-12]. Our study is the first to use a quasi-experimental
design to support an association between renal disease
and PPI exposure even after controlling for other known
causes of renal disease. Additionally, our study provides
the first estimate of an effect size for this relationship. We
found that patients with an incident of renal disease diag-
nosis were nearly twice as likely to have been exposed to
PPIs compared to those without renal disease.Table 5 Seondary analysis
Variable Cases Controls
Age (SD)c 45.49 (11.39) 44.31 (11.18)
Genderc
Female 109 (55.9%) 351 (57.8%)
Male 86 (44.1%) 256 (42.2%)
PPId use 15 (7.7%) 23 (3.8%)
NSAIDe use 58 (29.7%) 125 (20.6%)
Antibiotic use 45 (23.1%) 48 (7.9%)
Diuretic use 12 (6.2%) 8 (1.3%)
a OR odds ratio.
b CI confidence interval.
c Cases and controls were matched on age and gender so those variables were not
d PPI proton pump inhibitor.
e NSAID nonsteroidal anti-inflammatory drugs.Presently, AIN is not preventable due to its idiosyn-
cratic nature. Therefore it is important that emphasis be
placed on timely recognition. Early detection and treat-
ment (i.e., removal of the offending agent and possible
use of oral corticosteroids) have been shown to reduce
the morbidity of AIN [29]. Healthcare professionals are
recommended to have a heightened awareness of patient
complaints or clinical manifestations associated with
AIN and an understanding of their possible association
with PPIs. Pharmacists in particular are in a strategic
position to link changes in a patient’s health status with
recent PPI utilization.
Like all case–control studies, this analysis has limita-
tions. Misclassification bias can occur if subjects are
inaccurately classified regarding the outcome of interest
(i.e., renal disease) or the exposure being investigated
(i.e., PPI use). By more broadly defining PPI-associated
renal disease, we were able to capture more cases, but
we were also likely to have included instances of renal
injury not associated with PPI exposure. This misclassifi-
cation of cases could overestimate or underestimate the
true relationship between PPI use and renal disease, de-
pending on their distribution between exposure categor-
ies. Because our primary and secondary analysis
controlled for or removed potential confounders from
the analysis, we believe that the misclassified cases are
not likely to be associated with PPI use, which is
expected to make our estimate conservative.
Lack of OTC PPI utilization can lead to misclassifica-
tion of exposure. Because OTC use was not captured in
a claims database, it is possible that some subjects who
used OTC PPIs were misclassified as non-users. Table 3
shows that cases, patients with a renal disease diagnosis,
were more likely to be prescribed PPIs than controls. It
is likely, given the differences in underlying comor-
bidities, that cases also used more OTC PPIs. This
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leading to a more conservative estimate of association.
Surveillance bias could overestimate the impact of PPI
exposure. Surveillance bias can occur, as Gordis descri-
bed, “[i]f a population is monitored over a period of
time, disease ascertainment may be better in the
monitored population than in the general population…
which leads to an erroneous estimate of the relative risk
or odds ratio” [30]. In our study, individuals with renal
disease were more likely to have an underlying chronic
disease (Table 3). If subjects with chronic disease were
more likely to see a physician, it is also more likely that
a diagnosis of renal disease would have been made for
those subjects. In an effort to control for the effect of
surveillance bias, we created a second model where all
persons with chronic diseases were removed. Evidence
of an association between renal disease and PPI expo-
sure remained (OR = 2.25) in the sample population
without chronic diseases (Table 5).
Appropriate control of confounding variables is always
important in the analysis of observational studies. In
order to produce groups with similar important baseline
characteristics, we matched cases to multiple controls
based on age, gender, county of residence, and initial
date of coverage. Additionally, we controlled for other
causes of renal disease and health status, both directly
and with propensity scores. It is possible that even after
controlling for these known confounders, some residual
confounding variables remain. It is also possible that
additional confounding variables exist, such as OTC
NSAID use, which could not be controlled for in the
model, which is a limitation inherent to all obser-
vational studies.Conclusions
The results of this nested case-controlled study affirm an
association between renal disease and PPI use. Our study
revealed that patients with a renal disease diagnosis were
twice as likely to have a previous prescription for a PPI.
Therefore, it is necessary that pharmacist and physician
awareness and recognition of patient complaints or
clinical manifestations of this potentially harmful event
are increased. Furthermore, it is important that future
research seek to establish a definitive causal relationship.Abbreviations
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